CClinicalTrials.gg
CompletedNCT07192354Updated May 28, 2026

The Relationship Between Cyberchondria and Health Perception and Anxiety Level in Pregnant Women: A Cross-sectional Study

An observational study in Cyberchondria and Pregnancy, sponsored by Karabuk University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Karabuk University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
166
Ages
18 Years and older
Sex
Female
01

Study summary

Pregnancy is a unique period in which women require extensive health information both to protect their own health and to prepare for motherhood. The literature indicates that pregnant women most frequently seek information on healthy nutrition, physical activity, fetal development, pregnancy symptoms, childbirth preparation, vaccination, and medication use. Although health professionals are considered reliable sources of information, due to limited accessibility, pregnant women often turn to the internet and social media. This increases the risk of exposure to inaccurate or incomplete information and may sometimes lead to cyberchondria. Moreover, during pregnancy, factors such as educational level, socioeconomic conditions, and family relationships contribute to the frequent occurrence of anxiety disorders, which can negatively affect the mother's quality of life and fetal development. Health perception, on the other hand, is an important concept that shapes individuals' health behaviors and responsibilities. However, studies examining the relationship between cyberchondria, anxiety levels, and health perception in pregnant women are limited. This study aims to reveal the relationship between health information-seeking behaviors, health perception, and anxiety levels in this special population of pregnant women.

02

Conditions studied

  • Cyberchondria
  • Pregnancy
03

In context

Lead sponsor

Karabuk University is the lead sponsor of 126 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

pregnant women

Inclusion criteria

  • Must be 18 years or older, pregnant, have access to the internet at any time, and have the ability to use it.
  • Must be proficient in Turkish to understand the scales.

Exclusion criteria

Exclusion Criteria:

  • Having a diagnosed psychiatric illness,
  • Being a healthcare worker,
  • Having cognitive impairment or mental or physical limitations to the extent that they cannot understand questions.
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
166 participants (actual)
Patient registry
No

Interventions

  • OtherQuestionnaire and Physical Exam

    Participants will be administered the Cyberchondria Severity Scale Short Form (CSS-12), Health Perception Scale, and State and Trait Anxiety Scale online via Google form.

06

What researchers measure

Primary outcomes

  1. The Cyberchondria Severity Scale

    The Cyberchondria Severity Scale (CSS) was originally developed by McElroy and Shevlin (2014) to evaluate cyberchondria, defined as a form of anxiety characterized by excessive health-related information seeking on the internet. Subsequently, McElroy et al. (2019) introduced the short form of the scale, the CSS-12. The Turkish adaptation, validity, and reliability study of the CSS-12 was conducted by Söyler et al. (2021). The CSS-12 consists of 12 items, each rated on a 5-point Likert-type scale ranging from 1 ("never") to 5 ("always"). Total scores are calculated by summing all item responses, with possible scores ranging from 12 to 60. Higher scores indicate greater severity of cyberchondria. The scale does not contain any reverse-coded items. The CSS-12 comprises four subdimensions: excessiveness, distress, reassurance-seeking, and compulsion.

    Time frame: 1 month

  2. The Health Perception Scale

    The Health Perception Scale (HPS) was developed by Diamond et al. in 2007 to assess individuals' perceptions of their own health. The Turkish adaptation, including validity and reliability testing, was conducted by Kadıoğlu et al. in 2012. The scale consists of 15 items rated on a 5-point Likert-type scale, with response options ranging from "Strongly Disagree" to "Strongly Agree." Negative items are reverse-coded (Strongly Disagree = 5 to Strongly Agree = 1). The scale includes four subdimensions: central control, self-awareness, certainty, and importance of health. Total scores range from 15 to 75, with higher scores reflecting a more positive health perception. Participants indicate their agreement with each item, allowing researchers to quantify their overall health perception and examine its relationship with other psychosocial variables.

    Time frame: 1 month

  3. State-Trait Anxiety Inventory

    The State-Trait Anxiety Inventory (STAI) was originally adapted into Turkish by Öner and Le Compte between 1974 and 1977 to evaluate anxiety levels in both adolescent and adult Turkish populations. The inventory is widely used in research involving young and adult groups. The State Anxiety Scale items assess the intensity of feelings or behaviors in response to specific situations, with responses rated on a 4-point scale: 1 = Not at all, 2 = Somewhat, 3 = Much, 4 = Completely. The Trait Anxiety Scale items evaluate the frequency of feelings or behaviors over time, with response options: 1 = Almost never, 2 = Sometimes, 3 = Often, 4 = Almost always. The State Anxiety Scale consists of both direct items (3, 4, 6, 7, 9, 12, 13, 14, 17, 18) and reverse-scored items (1, 2, 5, 8, 10, 11, 15, 16, 19, 20). Similarly, the Trait Anxiety Scale includes direct items (22, 23, 24, 25, 28, 29, 31, 32, 34, 35, 37, 38, 40) and reverse-scored items (21, 26, 27, 30,

    Time frame: 1 month

07

Study locations

1 site
  • Karabuk University
    Karabük, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07192354
Lead sponsor
Karabuk University
Responsible party
Nurcan Contarli (Lecturer, Karabuk University) — Principal investigator
First posted
Sep 25, 2025
Start date
Oct 27, 2025
Primary completion
Dec 30, 2025
Completion
Jan 30, 2026
Last update
May 28, 2026

Study contacts

Tarik OZMEN, PhD
study chair · Karabuk University
Nesibe Sumeyye KUTAHYALIOGLU, PhD
principal investigator · Karabuk University
Nurcan CONTARLI, PhD
principal investigator · Karabuk University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion